NISCHR CRC Celebrates International Clinical Trials Day with Video Launch
International Clinical Trials Day will be celebrated around the world on 20 May 2013, marking the anniversary of what is regarded as the first clinical trial, carried out by James Lind in 1747.
The day aims to raise awareness of the importance of research to healthcare and highlights how partnerships between patients and healthcare practitioners are vital to high-quality, relevant research studies.
As part of celebrations for International Clinical Trials Day, NISCHR CRC has launched a new video aimed at researchers in Wales. It describes the support we can offer, with real-life examples of the way this support has made a difference to researchers.
Head to our NISCHR CRC YouTube Channel to watch the video.
Don’t forget that you can also now follow us on Twitter @NISCHR_CRC or through our Welsh language account @CRCcymraeg
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
